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Angiotensin II receptor antagonists in hypertension. Blockade of
the renin-angiotensin system is now recognized as an effective
approach to the treatment of hypertension and congestive heart
failure. Today, it is possible to antagonize the effects of angioten-
sin II more specifically by blocking its receptors by using nonpep-
tide receptor antagonists. These compounds that first have been
used to recognize the various subtypes of angiotensin II receptors
are now available clinically. Four of them have recently been
launched on the market and several others are preregistered for
the treatment of hypertension. These new molecules are as
effective as ACE inhibitors, calcium antagonists and beta-blockers
in lowering blood pressure in hypertensive patients. When com-
pared to ACE inhibitors, they appear to have comparable favor-
able effects on systemic and renal hemodynamic properties. One
of the major characteristics of angiotensin II receptor antagonists
as a class is the excellent tolerability with an incidence of side
effects that is generally similar to that of placebo. Large clinical
trials are now underway to demonstrate the long-term benefits of
these agents in hypertension, heart failure and type II diabetic
nephropathy.
Antihypertensive therapy enables to reduce considerably
the risk of developing cardiovascular complications. In-
deed, an overview of randomized drug trials in hyperten-
sion has recently shown that cardiovascular mortality can
be reduced by 20% if diastolic blood pressure is decreased
by 5 to 6 mm Hg [1]. Yet, several epidemiological studies
performed in North America and in Europe suggest that
patients with well-controlled blood pressure represent a
small fraction of the entire hypertensive population [2, 3].
Several explanations have been proposed for this finding
including non-compliance to long-term antihypertensive
therapy. Drug tolerance and the incidence of side effects
are important factors determining the long-term compli-
ance to drug therapy and recent results have demonstrated
that good compliance is significantly associated with the use
of newer agents such as angiotensin converting enzyme
(ACE) inhibitors [4]. Moreover, the persistence with anti-
hypertensive therapy is better with the newly well-tolerated
drugs [5].
In recent years, the trend in cardiovascular drug research
has been to develop new compounds acting on very specific
targets such as cell surface receptors. The increased selec-
tivity may improve the efficacy but more often reduces the
incidence of side effects. Several receptor antagonists have
been developed that block receptors involved in the control
of blood pressure such as the endothelin [6], bradykinin [7],
vasopressin [8, 9] and angiotensin II receptors [10]. Angio-
tensin II receptor antagonists, which selectively compete
with the binding of angiotensin II to its AT1 receptor
subtype, represent the most specific way to block the
activity of the renin-angiotensin system, a therapeutic ap-
proach that is now well recognized for the treatment of
hypertension and congestive heart failure. The purpose of
the present article is to highlight certain pharmacological
and clinical aspects of this new class of antihypertensive
agents.
ANGIOTENSIN II RECEPTOR ANTAGONISTS: A
RAPIDLY GROWING CLASS
Since the early development of losartan, the prototype of
a highly selective non-peptidic AT1 receptor antagonist,
several orally active angiotensin II antagonists have entered
under clinical investigation and are now available in various
countries. The pharmacological characteristics of the four
antagonists that have been launched are shown in Table 1
[10, 11]. Two other antagonists, eprosartan and telmisartan,
are being developed but have not been launched yet.
Losartan is a highly selective antagonist with an IC50 of
20 nM in rat vascular smooth muscle. It has no affinity for
the AT2 receptor subtype and no partial agonistic effect.
Losartan has a major active metabolite, EXP 3174, which is
20 times more potent than losartan and has a longer
duration of action (half-life of 6 to 9 hr for EXP3174 and
about 2 hr for losartan). On isolated vessels, losartan
produces a surmountable blockade of the contractile re-
sponse whereas EXP 3174 induces an insurmountable
blockade. Losartan clearance is primarily nonrenal but the
clearance of its metabolite occurs through both renal and
nonrenal routes. The bioavailability of losartan is 33% and
the compound is highly bound to proteins (.98%). Food
has no influence on drug absorption. The bioavailability of
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EXP3174 is very low. Thus, losartan is the drug on the
market but most of its effects are due to EXP3174.
Valsartan has been the second AT1 receptor antagonist
available clinically. It is also a potent AT1 antagonist with
an IC50 of 2.7 nM on rat aorta. Valsartan does not need to
be metabolized to develop its full activity and it is excreted
both in the bile (70%) and by the kidneys (30%). Its
bioavailability is about 25% and the half-life of six to nine
hours. The compound is also highly protein- bound (95%).
In acute studies, food decreases the absorption of valsartan
but the interaction with food does not appear to be
important during chronic administration. In experimental
models, the peak effect of valsartan occurs two to four
hours after dosing and the antihypertensive effect appears
to last for 24 hours.
Irbesartan is a long-acting angiotensin receptor antago-
nist with a plasma half-life of 11 to 15 hours. Its affinity for
the AT1 receptor is 1.3 nM in in rat liver. Irbesartan
produces an unsurmountable blockade of angiotensin II
binding. In contrast to losartan, but similar to valsartan, it
has also no active metabolite. Irbesartan has a bioavailabil-
ity of 60 to 80% and is only 90% bound to proteins. Food
has no effect on gastrointestinal absorption of irbesartan.
Irbesartan is cleared mainly by the liver (78%) and by the
kidneys (22%).
Candesartan cilexitil is also a long-acting antagonist of
AT1 receptors. Candesartan cilexitil is an ester carbonate
prodrug that is converted in vivo to CV 11974 [10]. The CV
11974 molecule is a potent antagonist of angiotensin II in
vitro (IC50 for the AT1 receptor of 28 nM in rabbit aorta).
The terminal half-life of candesartan is approximately nine
hours. The bioavaliability of candesartan is 42%. The
plasma protein binding of candesartan is 98%. Candesartan
is cleared mainly by the urine (60%) and to a lesser extent
through the bile (about 40%).
ANGIOTENSIN II RECEPTOR ANTAGONISTS:
EFFECTIVE ANTIHYPERTENSIVE AGENTS
Numerous controlled studies have been conducted with
the various angiotensin II antagonists to demonstrated
their antihypertensive efficacy. Thus, in placebo-controlled
studies, losartan as well as valsartan have been shown to be
effective antihypertensive drugs [12, 13]. A clear dose-
response relationship was not established, however, during
clinical development. In double-blind placebo-controlled
trials, irbesartan and candesartan also exerted a clinically
significant blood pressure lowering effect, but in contrast to
losartan and valsartan their effects were clearly dose-
dependent [14, 15]. With irbesartan, the dose-dependent
pattern was found between 75 and 300 mg whereas with
candesartan, the dose-response pattern was observed be-
tween 4 and 16 mg.
When compared to other antihypertensive classes, angio-
tensin II receptor antagonists possess an efficacy at least
equivalent to that of other antihypertensive agents includ-
ing angiotensin converting enzyme inhibitors, calcium an-
tagonists and beta-blockers [12–15]. Few studies have com-
pared the antihypertensive efficacy of two angiotensin II
receptor antagonists. In one study, candesartan (8 and 16
mg) was compared to losartan 50 mg and placebo in four
groups of about 80 patients with mild to moderate hyper-
tension [15]. Candesartan cilexetil 16 mg, that is, the
highest dose of candesartan, had a clinically and statistically
greater blood pressure lowering effect than losartan 50 mg
24 hours after administration, suggesting that candesartan
is more effective. However, candesartan is not more effec-
tive than losartan at peak effect. Moreover, the authors
have not compared the highest dose of losartan with the
highest dose of candesartan. Thus, the observed difference
may be due to the dose as well as to the duration of action
of the drugs. The comparative efficacy of irbesartan and
losartan as treatment of mild to moderate hypertension has
also been assessed in a double-blind study [14]. The drugs
were administered at fixed dosages that is, losartan 100
mg/day, irbesartan 150 or 300 mg/day for eight weeks. In
this study, irbesartan 300 mg but not 150 mg reduced
trough blood pressure to a significantly greater extent than
losartan 100 mg/day, and the percentage of patients with
normal blood pressure after eight weeks was higher with
irbesartan 300 mg/day. The peak effects of irbesartan and
losartan are again not known. The results of these two
studies would suggest that long-acting angiotensin II antag-
onists are slightly more effective than losartan. Yet, addi-
tional studies are needed to confirm these data and to
evaluate whether such differences are clinically relevant
when examining hard end-points such as morbidity and
mortality.
When the renin-angiotensin system is blocked, blood
Table 1. Pharmacological characteristics of the four angiotensin II receptor antagonists available on the market
Drug
name
Trade
name
Active
metabolite
Bioavailability
%
Dose
recommended
mg/day
Half-life
hours
Protein binding
%
Losartan Cosaar Yes 33 50–100 2 98.7
EXP 3171 6–9 99.8
Valsartan Diovan No 25 80–160 6 95.0
Irbesartan Aprovel No 60–80 150–300 11–15 90.0
Candesartan Atacand Yes 42 4–16 3–4 99.5
CV-11974 3–11
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pressure becomes salt-sensitive. Thus, diuretics represent a
logical combination to enhance the blood pressure re-
sponse in patients treated with angiotensin converting
inhibitors or angiotensin II antagonists. Several clinical
studies have demonstrated that angiotensin II antagonists
are highly effective when co-administered with hydrochlo-
rothiazide [14–16]. The antihypertensive efficacy of angio-
tensin II antagonists has also been examined in special
populations. No differential effect of the antagonists was
observed on the basis of age and gender. The blood
pressure response to angiotensin II receptor blockade
appears to be slightly less pronounced in black hypertensive
patients.
ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN
EXCELLENT TOLERABILITY PROFILE
The adverse event profile of a new therapeutic agent is
very important. One of the major characteristics of angio-
tensin II receptor antagonists as a class is the excellent
tolerability with an incidence of side-effects that is gener-
ally similar to that of placebo. Studies performed with
losartan and valsartan have clearly demonstrated that in
contrast to ACE inhibitors, these agents do not induce
cough [17, 18]. This observation confirms that dry cough is
due to the lack of specificity for the renin-angiotensin
system of ACE inhibitors. The only difference among
angiotensin II antagonists is the ability of losartan to
increase urinary uric acid excretion and hence to lower
plasma uric levels [19]. Whether this uricosuric effect of
losartan, but not EXP 3174, represents an advantage or an
inconvenience is still not clear. In patients pretreated with
thiazide diuretics, losartan has been shown to blunt signif-
icantly the diuretic-induced increase in plasma uric acid
[16]. In cyclosporine-treated heart transplant patients, lo-
sartan has also been shown to lessen the cyclosporine-
induced hyperuricemia [20]. Thus, in some clinical situ-
ations–if not always–the uricosuric effect of losartan may be
rather beneficial. Uric acid stone formation is not a com-
plication of losartan because urinary pH tends to become
slightly more alcaline during angiotensin II receptor block-
ade.
RENAL EFFECTS OF ANGIOTENSIN II
ANTAGONISTS: COMPARABLE TO THOSE OF ACE
INHIBITORS
In contrast to ACE inhibitors, angiotensin II receptor
antagonists are not expected to be associated with any
effect related to the inhibition of kininase II or with an
increase in prostaglandins. Thus, the influence of angioten-
sin II antagonists on renal hemodynamics and urinary
electrolyte excretion and their ability to protect renal
function might possibly differ. The results obtained so far in
experimental and clinical studies suggest rather that ACE
inhibitors and angiotensin II receptor antagonists have
similar effects on the kidney [19, 21–23]. Indeed, several
studies have demonstrated that angiotensin II antagonists
have no effect on glomerular filtration and increase renal
blood flow. This renal hemodynamic response to angioten-
sin II receptor blockade has been found in normotensive
subjects [19–21] as well as in hypertensive patients [22, 23].
Angiotensin II antagonists also increase urinary sodium
excretion [19, 21]. It has once been postulated that the
inhibition of prostaglandin metabolism is responsible for
the ACE-inhibitor-induced natriuresis. In a recent study,
we have found that indomethacin similarly abolishes the
natriuretic response to ACE inhibition and angiotensin II
receptor blockade in normotensive subjects [24]. This sug-
gests that the anti-natriuretic effect of nonsteroidal anti-
inflammatory drugs (NSAIDs) is not class-specific. Thus,
one could expect clinically that NSAIDs blunt the antihy-
pertensive effect of angiotensin II antagonists as they do
with ACE inhibitors and diuretics.
Finally, ACE inhibitors are known to have a favorable
impact on renal function because they reduce proteinuria.
Preliminary experimental and clinical studies obtained with
the angiotensin II receptor antagonists on small groups of
patients suggest that these agents have the same capacity to
lower urinary albumin excretion [22].
ANGIOTENSIN II ANTAGONISTS AND ACE
INHIBITORS: A USEFUL COMBINATION?
Acute inhibition of ACE results in a marked decrease in
plasma angiotensin II levels to almost undetectable levels
[25, 26]. However, this is not the case during chronic ACE
inhibition. Indeed, although blood pressure is reduced
throughout the day with the repeated administration of an
ACE inhibitor, plasma angiotensin II levels are still mea-
surable. The lack of complete disappearance of angiotensin
II from plasma during chronic treatment can be explained
in several ways. First, plasma renin activity and plasma
angiotensin I levels increase markedly during ACE inhibi-
tion. Since ACE activity is rarely inhibited around the clock
with ACE inhibitors, even a small percentage of enzyme
activity can lead to the generation of angiotensin II if the
substrate, that is, angiotensin I, is available in large
amounts [27]. Second, during chronic ACE inhibition,
angiotensin II can be formed by other enzymatic pathways
including for example the heart chymase [28]. Thus, addi-
tional antihypertensive effects could be theoretically ex-
pected from the combination of an ACE inhibitor with an
AT1 receptor antagonist because the antagonist blocks
angiotensin II at its receptor independently of its source.
However, if the antagonist effectively blocks all the effects
of angiotensin II independently of the level of circulating
angiotensin II, the need for an ACE inhibitor would be
doubtful. Plasma angiotensin II levels increase markedly
during chronic bockade of AT1 receptors. The elevated
plasma angiotensin II levels can be expected to compete
with the antagonist at the receptor site and to displace the
antagonist from the receptor. In this situation, the added
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ACE inhibitor could blunt the rise in plasma angiotensin II
and thereby increase the antihypertensive efficacy of the
receptor antagonist. Whether this hypothesis holds true in
clinical hypertension, and more precisely, whether high
circulating angiotensin II levels are indeed able to compete
with the mostly unsurmountable receptor blockade, cer-
tainly deserves further investigation. A preliminary study
conducted in salt-depleted normotensive volunteers has
already suggested that the combined administration of a
standard single oral dose of an ACE inhibitor and an
angiotensin II antagonist induces an additional blood pres-
sure reduction and has a major additive effect on the rise in
plasma renin activity [29]. Similar results were found in
transgenic rats with a renin dependent hypertension [30].
However, in rats with 5/6 renal mass ablation, enalapril,
losartan and the combination of both agents had similar
renoprotective effects that were closely related to the
magnitude of the antihypertensive effects [31]. Further
studies are need to decide whether the combination of an
ACE-inhibitor with an AT1 receptor antagonist provides
additive, or even synergistic, therapeutic benefits in pa-
tients with hypertension, heart failure of diabetic nephrop-
athy. In congestive heart failure, high doses of ACE
inhibitors are often necessary to block the renin-angioten-
sin system. In this condition, the association of an ACE
inhibitor and an AT1 receptor antagonist could seem
attractive to improve the overall blockade of the system.
However, to demonstrate the advantages of the ACE
inhibitor-AT1 antagonist combination, it should be com-
pared clinically with a full titration of each individual drug
and also with using long-acting angiotensin II antagonists.
THE FUTURE OF ANGIOTENSIN II RECEPTOR
ANTAGONISTS
Non-peptide, orally active angiotensin II antagonists
represent an important new development in the treatment
of hypertension and probably congestive heart failure and
chronic renal failure. These agents are very effective in
lowering blood pressure and present a unique tolerability
profile. Additional studies are now necessary to evaluate
their impact on the long-term morbidity and mortality of
patients with various cardiovascular diseases. Several large
trials are underway in various populations. The LIFE study
(Losartan Intervention For End-point reduction in hyper-
tension) is evaluating the effect of losartan on cardiovas-
cular morbidity and mortality in hypertensive patients [32]
and the RENAAL study examine the renal protective effect
of losartan in patients with type II diabetes. The ELITE
trial (Evaluation of Losartan In The Elderly) has compared
the safety and efficacy of losartan and captopril in elderly
patients with heart failure [33]. The first results of this study
have shown that losartan is as safe as captopril, and no
difference in renal dysfunction was found between the two
drugs. Surprisingly, however, after one year of follow-up
the mortality was signficantly lower in the losartan than in
the captopril group. A second study (ELITE II) is now
underway to confirm these promising preliminary results.
Large interventional trials are also conducted with other
angiotensin II receptor antagonists. Together, the results of
these studies will help to more clearly define the future role
of angiotensin II receptor antagonists in the management
of patients suffering from hypertension, congestive heart
failure and chronic nephropathies. At the same time, they
will contribute significantly to further elucidate the role of
angiotensin II in causing cardiovascular morbidity and
mortality.
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